Labcorp (LH) investor relations material

Strategic outlook and guidance

• Reaffirmed long-term guidance through 2026, projecting 5%-8% revenue growth and double-digit EPS growth, with margin accretion of 75-150 basis points and strong free cash flow.

• Specialty testing in oncology, women's health, autoimmune disease, and neurology identified as key growth drivers, with these segments outpacing market growth.

• Acquisitions expected to contribute 1.5%-2.5% to revenue growth, supported by a robust pipeline, especially in hospital and regional laboratory sectors.

• Technology and AI investments are central to improving customer experience, reducing costs, and transforming business operations, with LaunchPad savings targeted at $125M-$150M annually.

• Guidance incorporates potential headwinds such as PAMA, ACA, and Medicaid, with scenario planning and payer diversification mitigating risks.

Utilization trends and business mix

• Diagnostic utilization remains strong, with increasing tests per accession driven by specialty testing and new diagnostic offerings.

• Esoteric testing now comprises 41% of revenue, up from 38% in 2024, reflecting a favorable mix shift.

• Central laboratory business is robust, with over 70% of revenue from large pharma and biotech, primarily focused on durable, multi-year phase III trials.

• Invitae acquisition fully integrated, exceeding revenue and profitability expectations, and supporting new product launches.

Oncology and specialty testing focus

• Oncology is a major growth area, with over 50% of clinical trial services in oncology or neurology.

• Focus on therapy selection and molecular residual disease (MRD) in liquid biopsy, with a broad MRD pipeline across tumor types.

• Neurology, especially Alzheimer's disease, is the fastest-growing specialty segment.

• Higher tests per accession in specialty testing significantly boost profitability due to fixed infrastructure.